tirzepatide cardiovascular outcomes trial Effects of on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity Impact of Body Mass Index,

Furthermore, obesity (with high abdominal fat rather than BMI) is another prominent risk factor for both conditions

Based on Phase 2 trial data, the most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, which are most pronounced during dose escalation

According to a 2023 report from Trilliant Health, prescriptions for glucagon-like peptide-1 receptor agonist (GLP-1) medications a class of drug that includes semaglutide increased by 300 percent from the start of 2020 to the end of 2022

Current challenges surrounding exosome treatments

Major insurers such as UnitedHealthcare, Cigna, Blue Cross Blue Shield, Aetna, Medicare Part D, and Medicaid may offer coverage for medically necessary weight loss treatment